This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Halter, S. A. Articles by Coffey, R. J. Search for Related Content PubMed PubMed Citation Articles by Halter, S. A. Articles by Coffey, R. J.

American Journal of Pathology, Vol 140, 1131-1146, Copyright © 1992 by American Society for Investigative Pathology

REGULAR ARTICLES

Distinctive patterns of hyperplasia in transgenic mice with mouse mammary tumor virus transforming growth factor-alpha. Characterization of mammary gland and skin proliferations

SA Halter, P Dempsey, Y Matsui, MK Stokes, R Graves-Deal, BL Hogan and RJ Coffey
Department of Pathology, Vanderbilt University, Nashville, Tennessee 37232-2561.

Eight lines of transgenic mice expressing a mouse mammary tumor virus (MMTV) human transforming growth factor-alpha (TGF alpha) fusion gene were established. Three lines with distinctive phenotypes are presented. All have proliferative changes of the mammary gland. One line has sebaceous gland hyperplasia of the skin. Five histologic patterns of mammary gland hyperplasia based on two of these lines were identified: cystic hyperplasia, solid hyperplasia, dysplasia, adenoma, and adenocarcinoma. Human TGF alpha mRNA and protein were produced in all patterns but appeared reduced in solid hyperplasia, dysplasia, and adenocarcinoma. TGF alpha immunoreactivity in the mammary tissue, cystic fluid, and serum did not show significant differences; hyperplasia developed in 65% of multiparous mice and 45% of virgin mice by 12 months of age. Adenocarcinoma developed in 40% of multiparous mice and 30% of virgin mice by 16 months of age. These transgenic lines may provide useful models of mammary and sebaceous gland hyperplasia analogous to human disease.

This article has been cited by other articles:

				M. L. Rothenberg, B. LaFleur, D. E. Levy, M. K. Washington, S. L. Morgan-Meadows, R. K. Ramanathan, J. D. Berlin, A. B. Benson III, and R. J. Coffey Randomized Phase II Trial of the Clinical and Biological Effects of Two Dose Levels of Gefitinib in Patients With Recurrent Colorectal Adenocarcinoma J. Clin. Oncol., December 20, 2005; 23(36): 9265 - 9274. [Abstract] [Full Text] [PDF]

				M. P. Cleary, S. C. Juneja, F. C. Phillips, X. Hu, J. P. Grande, and N. J. Maihle Leptin Receptor-Deficient MMTV-TGF-{alpha}/LeprdbLeprdb Female Mice Do Not Develop Oncogene-Induced Mammary Tumors Experimental Biology and Medicine, February 1, 2004; 229(2): 182 - 193. [Abstract] [Full Text] [PDF]

				A. E. Gorska, R. A. Jensen, Y. Shyr, M. E. Aakre, N. A. Bhowmick, and H. L. Moses Transgenic Mice Expressing a Dominant-Negative Mutant Type II Transforming Growth Factor-{beta} Receptor Exhibit Impaired Mammary Development and Enhanced Mammary Tumor Formation Am. J. Pathol., October 1, 2003; 163(4): 1539 - 1549. [Abstract] [Full Text] [PDF]

				V. Grunwald and M. Hidalgo Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment J Natl Cancer Inst, June 18, 2003; 95(12): 851 - 867. [Abstract] [Full Text] [PDF]

				X. Hu, S. C. Juneja, N. J. Maihle, and M. P. Cleary Leptin--A Growth Factor in Normal and Malignant Breast Cells and for Normal Mammary Gland Development J Natl Cancer Inst, November 20, 2002; 94(22): 1704 - 1711. [Abstract] [Full Text] [PDF]

				T. A. Rose-Hellekant, K. Gilchrist, and E. P. Sandgren Strain Background Alters Mammary Gland Lesion Phenotype in Transforming Growth Factor-{alpha} Transgenic Mice Am. J. Pathol., October 1, 2002; 161(4): 1439 - 1447. [Abstract] [Full Text] [PDF]

				M. P. Cleary, M. K. Jacobson, F. C. Phillips, S. C. Getzin, J. P. Grande, and N. J. Maihle Weight-Cycling Decreases Incidence and Increases Latency of Mammary Tumors to a Greater Extent Than Does Chronic Caloric Restriction in Mouse Mammary Tumor Virus- Transforming Growth Factor-{alpha} Female Mice Cancer Epidemiol. Biomarkers Prev., September 1, 2002; 11(9): 836 - 843. [Abstract] [Full Text] [PDF]

				B. R. Davies, A. M. Platt-Higgins, G. Schmidt, and P. S. Rudland Development of Hyperplasias, Preneoplasias, and Mammary Tumors in MMTV-c-erbB-2 and MMTV-TGF{alpha} Transgenic Rats Am. J. Pathol., July 1, 1999; 155(1): 303 - 314. [Abstract] [Full Text] [PDF]

				P. Norgaard, B. Law, H. Joseph, D. L. Page, Y. Shyr, D. Mays, J. A. Pietenpol, N. E. Kohl, A. Oliff, R. J. Coffey Jr., et al. Treatment with Farnesyl-Protein Transferase Inhibitor Induces Regression of Mammary Tumors in Transforming Growth Factor (TGF) {{alpha}} and TGF{{alpha}}/neu Transgenic Mice by Inhibition of Mitogenic Activity and Induction of Apoptosis Clin. Cancer Res., January 1, 1999; 5(1): 35 - 42. [Abstract] [Full Text] [PDF]

				F. Rage, D. F. Hill, M. Sena-Esteves, X. O. Breakefield, R. J. Coffey, M. E. Costa, S. M. McCann, and S. R. Ojeda Targeting transforming growth factor alpha  expression to discrete loci of the neuroendocrine brain induces female sexual precocity PNAS, March 18, 1997; 94(6): 2735 - 2740. [Abstract] [Full Text] [PDF]